Edgar Braendle

Edgar Braendle joined Autolus as Chief Development Officer in July 2021. Previously he served as Chief Medical Officer and Global Head of Development at Sumitomo Dainippon Pharma Oncology (SDPO), where he was responsible for leading the global oncology development programs of Sumitomo Dainippon.

At SDPO, he led the full range of development functions spanning from early and late-stage clinical development, medical affairs, clinical operation, project management, CMC, regulatory affairs, quality, bio-statistics, data management, PV & drug safety, and clinical pharmacology. Prior to that, he held the role of Executive VP, Head of Research and Development and Chief Medical Officer at Boston Biomedical Inc.

Previously, Dr. Braendle served as President and CEO of ARUP Laboratories, a national clinical and anatomic pathology reference laboratory. Prior to this, he spent more than a decade at Novartis, where he served as Senior Vice President and Global Head of Companion Diagnostics leading the company's precision medicine approach.

In an earlier role as Vice President, Global Head of Oncology Biologics, Dr. Braendle led the development of oncology biologics in early to late stages. He started his industry career at Schering AG.

Dr. Braendle received a medical degree and training in hematologic malignancies and solid tumor oncology, pharmacology and urology at the University of Aachen, University of Bonn, and the University of Ulm in Germany.